Case Reports
27 May 2013
Vol. 65 No. 2 (2013)
https://doi.org/10.4081/reumatismo.2013.75

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Ulcerative colitis, Rheumatoid arthritis, Adalimumab.
2953
Views
886
Downloads

Authors

G. Andrisani
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
E. Gremese
Rheumatology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
L. Guidi
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
A. Papa
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
M. Marzo
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
C. Felice
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
D. Pugliese
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
A. Armuzzi
alearmuzzi@yahoo.com
Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ulcerative colitis (UC). Among all the biological agents available, nine have been currently approved for the treatment of RA. Conversely, only Infliximab and recently Adalimumab have been approved for UC. In particular, the efficacy of Adalimumab in UC has been demonstrated by both recent randomized controlled trials and real-life studies. Moreover, Adalimumab is a well-established treatment for RA. Herein, we describe a patient with RA and UC treated successfully with ADA.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

None
G. Andrisani, Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome
Internal Medicine and Gastroenterology Unit
E. Gremese, Rheumatology Unit, Complesso Integrato Columbus, Catholic University, Rome
Rheumatology Unit

How to Cite



Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis. (2013). Reumatismo, 65(2), 75-78. https://doi.org/10.4081/reumatismo.2013.75

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.